HC Wainwright reaffirmed their buy rating on shares of Edesa Biotech (NASDAQ:EDSA – Free Report) in a research note published on Thursday morning,Benzinga reports. HC Wainwright currently has a $21.00 price objective on the stock.
Edesa Biotech Price Performance
Shares of NASDAQ EDSA opened at $2.39 on Thursday. The firm’s 50 day simple moving average is $2.09 and its 200-day simple moving average is $2.78. Edesa Biotech has a 12 month low of $1.55 and a 12 month high of $5.59. The stock has a market capitalization of $16.71 million, a price-to-earnings ratio of -1.28 and a beta of 0.77.
Edesa Biotech (NASDAQ:EDSA – Get Free Report) last announced its quarterly earnings data on Friday, February 14th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.17). During the same quarter in the prior year, the firm posted ($0.54) earnings per share. Analysts anticipate that Edesa Biotech will post -1.75 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
About Edesa Biotech
Edesa Biotech, Inc, a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis.
Read More
- Five stocks we like better than Edesa Biotech
- When to Sell a Stock for Profit or Loss
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- Bank Stocks – Best Bank Stocks to Invest In
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- How to Choose Top Rated Stocks
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for Edesa Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edesa Biotech and related companies with MarketBeat.com's FREE daily email newsletter.